

# Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/G9672881C44EN.html>

Date: September 2018

Pages: 49

Price: US\$ 3,500.00 (Single User License)

ID: G9672881C44EN

## Abstracts

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018

### SUMMARY

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucose Dependent Insulinotropic Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas

Metabolic Disorders, Undisclosed and Respiratory which include indications Type 2 Diabetes, Obesity, Unspecified and Asthma.

Furthermore, this report also reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development

Amgen Inc

Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Dong-A Socio Holdings Co Ltd

Hyundai Pharmaceutical Co Ltd

Japan Tobacco Inc

Kowa Co Ltd

Merck & Co Inc

Novartis AG

Taisho Pharmaceutical Holdings Co Ltd

Yuhan Corp

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles

APD-597 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-1241 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-2982 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCO-094 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR119 Receptor for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-18420 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones

Featured News & Press Releases

Nov 04, 2010: Arena Pharmaceuticals Provides Update On GPR119 Portfolio For Type 2 Diabetes

Nov 05, 2009: Metabolex Closes \$8.6 Million Financing Round

Dec 15, 2008: Arena Pharmaceuticals Announces Initiation Of Phase I Clinical Trial Of Type 2 Diabetes Drug Candidate In Partnership With Ortho-McNeil-Janssen Pharmaceuticals

Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982

Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indication, H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Amgen Inc, H2 2018  
Pipeline by Arena Pharmaceuticals Inc, H2 2018  
Pipeline by CymaBay Therapeutics Inc, H2 2018  
Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018  
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018  
Pipeline by Japan Tobacco Inc, H2 2018  
Pipeline by Kowa Co Ltd, H2 2018  
Pipeline by Merck & Co Inc, H2 2018  
Pipeline by Novartis AG, H2 2018  
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018  
Pipeline by Yuhan Corp, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Amgen Inc

Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Dong-A Socio Holdings Co Ltd

Hyundai Pharmaceutical Co Ltd

Japan Tobacco Inc

Kowa Co Ltd

Merck & Co Inc

Novartis AG

Taisho Pharmaceutical Holdings Co Ltd

Yuhan Corp



## I would like to order

Product name: Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/G9672881C44EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9672881C44EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

